UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

267P Real-life study with PRODIGE 23 protocol in stage II and III rectal cancer: Experience of an Algerian oncological center

Annals of oncology, 2024-06, Vol.35, p.S112-S113

2024

Volltextzugriff (PDF)

Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial

Journal of cancer research and clinical oncology, 2023-08, Vol.149 (9), p.6171-6179

2023

Volltextzugriff (PDF)

39P Neuroendocrine neoplasms: A retrospective analysis in a single Algerian institution

ESMO open, 2023-03, Vol.8 (1), p.101060, Article 101060

2023

Volltextzugriff (PDF)

Epidemiology of breast cancer in women based on diagnosis data from oncologists and senologists in Algeria

Cancer treatment and research communications, 2020, Vol.25, p.100220-100220, Article 100220

2020

Volltextzugriff (PDF)

Biomarker testing practices in the SECURE (proSpective obsErvational clinical practiCe stUdy in the first-line management of metastatic colorectal cancer [mCRC] with eRbitux in combination with chemothErapy) study

Annals of oncology, 2017-09, Vol.28, p.v195-v195

2017

Volltextzugriff (PDF)

Middle East & North Africa registry to characterize RAS mutation status and tumour specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)

Annals of oncology, 2019-10, Vol.30, p.v246

2019

Volltextzugriff (PDF)

656PMiddle East & North Africa registry to characterize RAS mutation status and tumour specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

656P - Middle East & North Africa registry to characterize RAS mutation status and tumour specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)

Annals of oncology, 2019-10, Vol.30, p.v246-v246

2019

Volltextzugriff (PDF)

P-9 A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer

Annals of oncology, 2020-07, Vol.31, p.S92

2020

Volltextzugriff (PDF)

Bevacizumab plus oxaliplatine, acide folinique et 5-fluoro-uracile (Folfox7) en première ligne de traitement des cancers colorectaux évolués et/ou métastatiques

Bulletin du cancer, 2010-04, Vol.97 (4), p.469-474

2010

Volltextzugriff (PDF)

An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

European journal of cancer (1990), 2018-04, Vol.92, p.S102-S103

2018

Volltextzugriff (PDF)

363 (PB-158) - An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

European journal of cancer (1990), 2018-04, Vol.92, p.S102-S103

2018

Volltextzugriff (PDF)

198PA multicentre, international neoadjuvant (NA), randomized, double-blind phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib in patients with operable luminal breast cancer (SAFIA Trial)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

A multicentre, international neoadjuvant (NA), randomized, double-blind phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib in patients with operable luminal breast cancer (SAFIA Trial)

Annals of oncology, 2019-10, Vol.30, p.v67

2019

Volltextzugriff (PDF)

198P - A multicentre, international neoadjuvant (NA), randomized, double-blind phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib in patients with operable luminal breast cancer (SAFIA Trial)

Annals of oncology, 2019-10, Vol.30, p.v67-v67

2019

Volltextzugriff (PDF)

Bevacizumab plus oxaliplatine, acide folinique et 5-fluoro-uracile (Folfox7) en première ligne de traitement des cancers colorectaux évolués et/ou métastatiques: Spécial Maghreb

Bulletin du cancer, 2010, Vol.97 (4), p.469-474

2010

Volltextzugriff (PDF)

Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)

Bulletin du cancer, 2010-04, Vol.97 (4), p.469

2010

Volltextzugriff (PDF)

Utilisation d’une méthode d’analyse prospective des risques pour améliorer la sécurité du processus chimiothérapie anticancéreuse dans un service d’oncologie médicale en Algérie

Le pharmacien hospitalier & clinicien, 2016-03, Vol.51 (1), p.40-50

2016

Volltextzugriff (PDF)

Bevacizumab plus FOLFOX7 as first line treatment in patients with advanced colorectal cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e15092-e15092

2009

Volltextzugriff (PDF)

Oxaliplatin (OXA)/5-fluorouracil (5FU)/folinic acid (FA) in patients (pts) with advanced colorectal cancer (ACRC): Report of an Algerian trial

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3734-3734

2005

Volltextzugriff (PDF)

Gemcitabine (G) and cisplatin (C) in the treatment of locally advanced and/or metastatic pancreatic carcinoma

European journal of cancer (1990), 2001-04, Vol.37, p.S288-S288

2001

Volltextzugriff (PDF)

Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.596-596

2022

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(22)

Sprache

Englisch
(18)
Französisch
(4)

Erscheinungsjahr

n.n

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

267P Real-life study with PRODIGE 23 protocol in stage II and III rectal cancer: Experience of an Algerian oncological center

Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial

39P Neuroendocrine neoplasms: A retrospective analysis in a single Algerian institution

Epidemiology of breast cancer in women based on diagnosis data from oncologists and senologists in Algeria

Biomarker testing practices in the SECURE (proSpective obsErvational clinical practiCe stUdy in the first-line management of metastatic colorectal cancer [mCRC] with eRbitux in combination with chemothErapy) study

Middle East & North Africa registry to characterize RAS mutation status and tumour specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)

656PMiddle East & North Africa registry to characterize RAS mutation status and tumour specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)

656P - Middle East & North Africa registry to characterize RAS mutation status and tumour specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)

P-9 A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer

Bevacizumab plus oxaliplatine, acide folinique et 5-fluoro-uracile (Folfox7) en première ligne de traitement des cancers colorectaux évolués et/ou métastatiques

An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

363 (PB-158) - An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

198PA multicentre, international neoadjuvant (NA), randomized, double-blind phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib in patients with operable luminal breast cancer (SAFIA Trial)

A multicentre, international neoadjuvant (NA), randomized, double-blind phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib in patients with operable luminal breast cancer (SAFIA Trial)

198P - A multicentre, international neoadjuvant (NA), randomized, double-blind phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib in patients with operable luminal breast cancer (SAFIA Trial)

Bevacizumab plus oxaliplatine, acide folinique et 5-fluoro-uracile (Folfox7) en première ligne de traitement des cancers colorectaux évolués et/ou métastatiques: Spécial Maghreb

Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)

Utilisation d’une méthode d’analyse prospective des risques pour améliorer la sécurité du processus chimiothérapie anticancéreuse dans un service d’oncologie médicale en Algérie

Bevacizumab plus FOLFOX7 as first line treatment in patients with advanced colorectal cancer

Oxaliplatin (OXA)/5-fluorouracil (5FU)/folinic acid (FA) in patients (pts) with advanced colorectal cancer (ACRC): Report of an Algerian trial

Gemcitabine (G) and cisplatin (C) in the treatment of locally advanced and/or metastatic pancreatic carcinoma

Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant

Suchergebnisse filtern